Last reviewed · How we verify
Lidocaine 5% patch
Lidocaine blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses to produce local anesthesia.
Lidocaine blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Postherpetic neuralgia (localized neuropathic pain), Localized pain relief.
At a glance
| Generic name | Lidocaine 5% patch |
|---|---|
| Also known as | Lidoderm, Lidoderm® (Endo Pharmaceuticals Inc, Malvern, PA, USA), Ebanel, UBER NUMB, Lidocaine patch |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that works by inhibiting sodium influx through sodium-selective channels in the nerve cell membrane, thereby preventing depolarization and blocking action potential propagation. When applied topically as a 5% patch, it penetrates the skin to anesthetize peripheral nerves in the area of application. This mechanism provides localized pain relief without systemic effects.
Approved indications
- Postherpetic neuralgia (localized neuropathic pain)
- Localized pain relief
Common side effects
- Skin irritation or erythema at application site
- Contact dermatitis
- Localized edema
Key clinical trials
- Predictors of Treatment Response to Stellate Ganglion Block in Cervical Radicular Pain
- Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches (PHASE3)
- Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department (PHASE4)
- Frozen Shoulder and Hormone Replacement Therapy (PHASE4)
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
- Connective Tissue Matrix for Rotator Cuff Tendinopathy (PHASE4)
- The Comparison of Navigational Bronchoscopic and CT-Guided Preoperative Markings in Minimally Invasive Thoracic Surgery (NA)
- The OBstetric Lidocaine Patch (OBLido) Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine 5% patch CI brief — competitive landscape report
- Lidocaine 5% patch updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI